Nilotinib (AMN-107)
Catalog No. A10644
Nilotinib (AMN-107)是一种Bcr-Abl抑制剂,IC50小于30 nM。
- Rami Shinnawi, .et al. Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters, Stem Cell Reports, 2015, Oct 13; 5(4): 582-596 PMID: 26372632
- Tetsuya Saita, .et al. Preparation of Antibodies and Development of an Enzyme-Linked Immunosorbent Assay for the Tyrosine Kinase Inhibitors Lapatinib and Nilotinib., Biol Pharm Bull. , 2015, 38(10):1652-7 PMID: 26424026
Catalog Num | A10644 |
---|---|
M. Wt | 529.5 |
Formula | C28H22F3N7O |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 641571-10-0 |
Synonyms | AMN107 |
SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5 |
Nilotinib (AMN-107)是一种Bcr-Abl抑制剂,IC50小于30 nM。
Targets
Bcr-Abl (Murine myeloid progenitor cells) | ||||
<30 nM |
In vitro (25°C) | DMSO | 26 mg/mL (49.09 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 4% DMSO+30% PEG 300+5% Tween 80+ddH2O | 2 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.89 mL | 94.43 mL | 188.86 mL |
0.5 mM | 3.78 mL | 18.89 mL | 37.77 mL |
1 mM | 1.89 mL | 9.44 mL | 18.89 mL |
5 mM | 0.38 mL | 1.89 mL | 3.78 mL |
*The above data is based on the productmolecular weight 529.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.